In particular, aberrant MAFB activity has been associated with the progression of diseases such as multiple myeloma and acute myeloid leukemia as well as other solid tumors, where it may contribute to the survival and proliferation of malignant cells, thereby promoting disease progression. This evidence concerns the gene MAFB and plasma cell myeloma.